https://teadreceptor.com
The impact of adjuvant or neoadjuvant chemotherapy on the progression and survival of patients with craniofacial bone sarcomas is still poorly understood. Survival outcomes were scrutinized to identify whether discrepancies existed among patient groups that received either neoadjuvant or adjuvant chemotherapy treatment. Employing the TriNetX network (TriNetX, Cambridge, MA, USA), a retrospective review of adult patients diagnosed with malignant craniofacial bone tumors (ICD-10 codes C410-C411) within the 20 years prior to April 28, 2022, was undertaken. Adjuvan
Suka
Komentar
Membagikan
